Categories
Publications

FDA Approves First Oral Blood Thinning Medication for Children – FDA

Today, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a condition where blood clots form in the veins) directly after they have been treated with a blood thinner given by injection for at least five days. The FDA also approved Pradaxa oral pellets to prevent recurrent clots among patients 3 months to less than 12 years old who completed treatment for their first venous thromboembolism.

http://archive.today/2021.11.03-234924/https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-blood-thinning-medication-children